Quarterly ResultOct 29, 2026, 07:07 AM
Incyte Q3 Revenue $1.56B (+14% YoY); Raises 2026 Guidance
AI Summary
Incyte Corporation reported strong third quarter 2026 financial results, with total revenue increasing 14% year-over-year to $1.56 billion and total net sales rising 14% to $1.32 billion. The company raised its full-year 2026 financial guidance for key products and segments. Significant pipeline progress was also highlighted, including positive Phase 1 data for INCB161734 and INCA033890, and the completion of the Vega Therapeutics acquisition in July.
Key Highlights
- Incyte reported Q3 2026 total revenue of $1.56 billion, up 14% YoY.
- Total net sales reached $1.32 billion in Q3 2026, a 14% increase YoY.
- Jakafi net sales were $827 million, up 4% YoY.
- Opzelura cream net sales increased 36% YoY to $255 million.
- Hematology and Oncology portfolio net sales grew 38% YoY to $235 million.
- Raised 2026 full-year financial guidance for Opzelura, Hematology and Oncology, and total net sales.
- Acquired Vega Therapeutics for $1.25 billion in July 2026.
- Phase 1 data for INCB161734 and INCA033890 support expanding GI Oncology strategy.
Price Impact
More from INCY